Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Accelerated Community Oncology Research Network or ACORN has initiated double-blind, randomized Phase IIb clinical trial evaluating the efficacy of Nexavar tablets in combination with gemcitabine in patients with metastatic breast cancer whose cancer has progressed during or after treatment with bevacizumab or Avastin.
Subscribe to our email newsletter
The trial will enroll a total of 220 patients at approximately 45 sites in approximately 20 states and will assess efficacy, safety and patient quality of life as endpoints. Patients will be randomly assigned to receive either Nexavar and gemcitabine, or placebo and gemcitabine (Gemzar).
ACORN will enroll research sites, provide contract and budgeting services, foster the accrual of patients at the site level, collect data and monitor its accuracy, and provide overall project management for the trial.